Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled KB408 for Alpha-1 Antitrypsin Deficiency
NCT06049082Phase 1Recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of KB408 in alpha-1 antitrypsin deficiency (AATD) (4 cohorts), sponsored by Krystal Biotech, Inc. Primary endpoint: Safety and Tolerability Assessment at 3 months. Started Feb 2024; status: recruiting.
02
Drugs
KB408
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06049082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049082.